Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

Marachelian Araz; Desai Ami; Balis Frank; Katzenstein Howard; Qayed Muna; Armstrong Michael; Neville Kathleen A.; Cohn Susan L.; Bush Mark; Gunawan Rudy; Lim Allison Pecha; Smith Malcolm A.; Smith L. Mary

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

【24h】

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

机译：小儿清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学，安全性和耐受性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Dinutuximab (Unituxin (TM); ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United Therapeutics Corporation (UTC) assumed ch14.18 production from the National Cancer Institute (NCI); this study evaluates pharmacokinetic comparability, safety, and tolerability of UTC and NCI products.

机译：抗双唾液酸神经节苷脂的单克隆抗体Dinutuximab（Unituxin（TM）; ch14.18）作为高危神经母细胞瘤巩固治疗后的一部分提高了生存率。 United Therapeutics Corporation（UTC）假定国家癌症研究所（NCI）生产ch14.18;这项研究评估了UTC和NCI产品的药代动力学可比性，安全性和耐受性。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2016年第2期|共8页
作者
Marachelian Araz; Desai Ami; Balis Frank; Katzenstein Howard; Qayed Muna; Armstrong Michael; Neville Kathleen A.; Cohn Susan L.; Bush Mark; Gunawan Rudy; Lim Allison Pecha; Smith Malcolm A.; Smith L. Mary;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
ch14.18; Dinutuximab; Pharmacokinetics; Safety; Tolerability; Unituxin;

机译：ch14.18;Dinutuximab;药代动力学;安全性;耐受性;Unituxin;

相似文献

外文文献
中文文献
专利

1. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy [J] . Marachelian Araz, Desai Ami, Balis Frank, Cancer chemotherapy and pharmacology. . 2016,第2期

机译：小儿清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学，安全性和耐受性
2. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients [J] . Mora Jaume, Valero Miguel, DiCristina Cara, Pediatric blood & cancer . 2019,第6期

机译：FOSAPREPITANT用于预防化疗诱导的恶心和呕吐在儿科癌症患者中的药代动力学/药效学和耐受性
3. A series of case reports from JEWELFISH, an open-label study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of RG7916 in adult and pediatric patients with spinal muscular atrophy who previously participated in a study with another SMN2-targeting therapy [J] . Chiriboga C., Mercuri E., Fischer D., Neuromuscular disorders: NMD . 2017,第Suppla2期

机译：来自Jewevelever的一系列案例报告，开放标签研究，以研究成人和儿科肌萎缩的RG7916中RG7916的安全性，耐受性和药代动力学/药效学，脊柱肌肉萎缩患者以前参加了另一种SMN2靶向治疗的研究
4. Therapy of Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Efficacy, Tolerability, and Safety of a New Nanofiltered Intravenous Immunoglobulin [C] . H.-H. Wolf, S. Davies, G. Smith, European Haematology Association . 2002

机译：慢性免疫血小板减少症患者的治疗患者（ITP）：一种新的纳米过滤静脉内免疫球蛋白的疗效，耐受性和安全性
5. Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability. [D] . Ivaturi, Vijay Deep. 2010

机译：鼻内和直肠地西epa用于抢救治疗：药代动力学和耐受性评估。
6. Comparative pharmacokinetics safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy [O] . Araz Marachelian, Ami Desai, Frank Balis, -1

机译：儿科清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学安全性和耐受性
7. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy [O] . Araz Marachelian, Ami Desai, Frank Balis, 2016

机译：儿科清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学，安全性和耐受性

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

摘要

著录项

相似文献

相关主题

期刊订阅